In Section A, contributors will obtain unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. More participants will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "add-on" therapy. In Phase https://robinsonv010juf3.gynoblog.com/profile